Successful <scp>TS</scp>‐1 monotherapy as the second‐line treatment for advanced extramammary Paget's disease: A report of two cases

Kato, Junji; Hida, Tokimasa; Yamashita, Toshiharu; Kamiya, Shiori; Sato, Sayuri; Takahashi, Hitomi; Sawada, Masahide; Yamada, Megumi; Uhara, Hisashi

doi:10.1111/1346-8138.14017

Cited by 19 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kato et al . recently reported favorable response in two patients with TS‐1 monotherapy following docetaxel resistance . As nearly 60% of EMPD demonstrates HER2 gene amplification, trastuzumab and paclitaxel have yielded favorable responses in many individual reports .…”

Section: Nonsurgical Interventionsmentioning

confidence: 99%

Extramammary Paget's disease: a review of the literature

2018

View full text Add to dashboard Cite

Extramammary Paget's disease (EMPD) is a rare cutaneous malignancy. The disease typically affects older individuals aged 60-80 years and is seen most frequently in postmenopausal Caucasian women and Asian men. EMPD exhibits a predilection for the genital and perianal regions and may be associated with an underlying carcinoma in adjacent organs. EMPD presents a challenge in both diagnosis and management. Often treated empirically as various dermatitides, the correct diagnosis is frequently delayed by many years. Following diagnosis, an extensive search for an associated malignancy should be initiated. If invasive disease is present on biopsy, a sentinel lymph node biopsy may guide further treatment. Mohs micrographic surgery appears to be superior to wide local excision when considering tissue sparing ability and disease recurrence. Nonsurgical interventions have also been investigated with varied results. Regardless of treatment method, long-term follow-up is recommended to monitor for local disease recurrence, development of internal malignancy, regional lymphadenopathy, or distant metastasis.

show abstract

Section: Nonsurgical Interventionsmentioning

confidence: 99%

Extramammary Paget's disease: a review of the literature

2018

View full text Add to dashboard Cite

show abstract

“…Although several therapeutic modalities such as radiation therapy, chemotherapy, and molecular targeted therapy have been reported, their efficacy in treating unresectable EMPD is unsatisfactory. Thus, new treatment modalities are required [4,[12][13][14].…”

Section: Introductionmentioning

confidence: 99%

NECTIN4 Expression in Extramammary Paget’s Disease: Implication of a New Therapeutic Target

Murata

Ito

Tanaka

et al. 2020

IJMS

View full text Add to dashboard Cite

Extramammary Paget’s disease (EMPD) is a rare skin cancer arising in the anogenital area. Most EMPD tumors remain dormant as in situ lesions, but the outcomes of patients with metastatic EMPD are poor because of the lack of effective systemic therapies. Nectin cell adhesion molecule 4 (NECTIN4) has attracted attention as a potential therapeutic target for some cancers. Urothelial cancer is one such cancer, and clinical trials of enfortumab vedotin, a drug-conjugated anti-NECTIN4 antibody, are ongoing. However, little is known regarding the role of NECTIN4 in EMPD. In this study, we conducted immunohistochemical analysis of NECTIN4 expression in 110 clinical EMPD samples and normal skin tissue. In normal skin, positive signals were observed in epidermal keratinocytes (particularly in the lower part of the epidermis), eccrine and apocrine sweat glands, inner and outer root sheaths, and matrix of the hair follicles. The most EMPD lesions exhibited strong NECTIN4 expression, and high NECTIN4 expression was significantly associated with increased tumor thickness, advanced TNM stage, and worse disease-specific survival. These results support the potential use of NECTIN4-targeted therapy for EMPD. Our report contributes to the better understanding of the pathobiology of NECTIN4 in the skin and the skin-related adverse effects of NECTIN4-targeted therapy.

show abstract

“…Efficacy of TS-1 monotherapy has also been reported in small number of cases [135]. Kato et al reported two cases of advanced EMPD in which TS-1 monotherapy was effective as a second line after docetaxel treatment failure [136]. It has been reported that TS-1 plus docetaxel exhibit synergistic antitumor effects because docetaxel reduces 5-FU metabolites, resulting in increased 5-FU [137].…”

Section: Chemotherapiesmentioning

confidence: 98%

Extramammary Paget’s Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments

Ishizuki

Nakamura

2021

Current Oncology

View full text Add to dashboard Cite

Extramammary Paget’s disease (EMPD) is a rare neoplasm that usually develops in apocrine gland-bearing areas, such as the vulva, scrotum, and penis. EMPD may present with a focal, multifocal, or an ectopic lesion. Clinically, EMPD lesions often exhibit infiltrative erythema, which is sometimes similar to other skin disorders such as eczema. While primary EMPD arises as intraepithelial neoplasm of the epidermis, EMPD-like lesions may occur from epidermotropic spread of malignant cells or direct extension from an underlying internal neoplasm, known as secondary EMPD. Because treatment strategies differ for primary EMPD and secondary EMPD, accurate diagnosis based on detailed histopathological evaluation is required. In the early stages, EMPD usually shows indolent growth, and most cases are diagnosed as carcinoma in situ. However, invasive lesions may result in metastases, and deep invasion is associated with high incidence of metastases. Conventional chemotherapies have been used for EMPD treatment in patients with distant metastases, but the efficacy is not satisfactory, and the prognosis for such patients remains poor. Recent studies have provided various insights into the molecular pathogenesis of the development and advancement of EMPD, which may lead to novel treatment approaches for metastatic EMPD. This review addresses the diagnosis, pathogenesis, and treatment of EMPD with focus on recent progress in understanding this disease.

show abstract

Successful TS‐1 monotherapy as the second‐line treatment for advanced extramammary Paget's disease: A report of two cases

Cited by 19 publications

References 9 publications

Extramammary Paget's disease: a review of the literature

Extramammary Paget's disease: a review of the literature

NECTIN4 Expression in Extramammary Paget’s Disease: Implication of a New Therapeutic Target

Extramammary Paget’s Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments

Contact Info

Product

Resources

About